Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (BRKR) delivers innovative analytical instrumentation and diagnostic solutions for life sciences, pharmaceuticals, and industrial applications. This news hub provides investors and industry professionals with timely updates on corporate developments, financial performance, and technological advancements.
Access comprehensive coverage of Bruker's press releases, including earnings reports, product launches, strategic partnerships, and regulatory milestones. Our curated news collection simplifies tracking market-moving events and understanding their impact on Bruker's position in scientific instrumentation markets.
Key content categories feature updates across Bruker's business segments - from BSI BioSpin's research tools to BEST's energy innovations. Stay informed about operational expansions, R&D breakthroughs, and quality assurance initiatives that drive the company's global success.
Bookmark this page for direct access to verified Bruker announcements and analysis. Monitor evolving trends in analytical technology through reliable updates from one of the industry's most established instrumentation providers.
Bruker Corporation (Nasdaq: BRKR) will participate in the 39th annual J.P. Morgan Healthcare Conference from January 11-14, 2021. Frank Laukien, the Chairman, President & CEO, along with CFO Gerald Herman, will present on January 11, 2021, at 3:40 PM EST. A live audio webcast of the presentation can be accessed on the Investor Relations section of Bruker's website. A replay will be available for 30 days post-event. Bruker aims to enable scientific discoveries through high-performance instruments and solutions in various life science applications.
Bruker Corporation (Nasdaq: BRKR) and Evosep have announced advancements in high-sensitivity, true single-cell proteomics using a modified timsTOF Pro mass spectrometer and Evosep One chromatography system. A study by the Mann-group achieved identification of up to 1,500 protein groups from single HeLa cells. Innovative ultra low-flow methods demonstrated 10x higher sensitivity at 100 nL/min gradients. The new technologies enable better single-cell analysis, critical for clinical diagnostics and biomarker discovery, with commercialization planned for 2022.
Bruker Corporation (Nasdaq: BRKR) has received US FDA clearance for the MBT Sepsityper Kit US IVD, designed for rapid identification of over 425 microorganisms from positive blood cultures. This innovative kit, utilized with the MALDI Biotyper CA System, significantly reduces the time-to-result by up to 24 hours compared to traditional methods, enhancing patient outcomes in suspected sepsis cases. Clinical experts highlight its affordability and efficiency, potentially improving antibiotic stewardship and healthcare resource management.
Bruker Corporation (Nasdaq: BRKR) has launched the FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel for simultaneous detection of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV). This CE-IVD labeled kit can process up to 96 PCR results in under two hours and has demonstrated 100% sensitivity and specificity in validation tests. The panel also accommodates saliva samples, offering convenience and efficiency for clinical labs. The launch reflects Bruker’s commitment to enhancing diagnostic capabilities during the winter virus season.
Bruker Corporation (Nasdaq: BRKR) will take part in the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 2:05 PM GMT (9:05 AM EST). CFO Gerald Herman will engage in an analyst Q&A session during the event. A live audio webcast can be accessed on Bruker's Investor Relations website, with a replay available for 30 days post-event. Bruker focuses on advancing scientific discovery through high-performance instruments and analytical solutions across various fields, enhancing research in life sciences and clinical applications.
Bruker Corporation (Nasdaq: BRKR) reported Q3 2020 revenues of $511.4 million, down 1.9% year-over-year. Organic revenue declined 4.6%, attributed to decreased demand from academic and industrial sectors amid the COVID-19 pandemic. Q3 GAAP operating income was $81.2 million with a margin of 15.9%, while non-GAAP operating income was $94.9 million, marking an 18.6% margin. Year-to-date revenues totaled $1.36 billion, a 7.7% decline. FY 2020 guidance remains suspended due to pandemic-related impacts.
Bruker Corporation (Nasdaq: BRKR) has introduced the Vutara VXL Super-Resolution Fluorescence Microscope, aimed at enhancing affordable, super-resolution imaging in biological research. This innovative system employs Bruker’s leading single-molecule localization technology, facilitating advanced studies of DNA, RNA, and proteins, as well as complex biological structures. Key features include high spatial resolution, multiplexing capabilities, and integrated analytical software, making it suitable for various research applications. The company aims to broaden access to 3D microscopy for the scientific community, potentially advancing cellular biology research.
Bruker Corporation (Nasdaq: BRKR) will release its third quarter 2020 financial results on November 2, 2020, after market close. A conference call will follow at 4:30 p.m. Eastern Time to discuss these results and current business trends. Investors can participate via webcast or telephone. Pre-registration is available to streamline entry. A replay of the call will be accessible until December 2, 2020, using the provided conference number.
Bruker Corporation (Nasdaq: BRKR) has launched the Fourier™ 80, an 80 MHz benchtop FT-NMR spectrometer, in Europe. The device features gradient spectroscopy and an optional CTC PAL® sample changer, enhancing throughput and efficiency. With a novel 80 MHz permanent magnet, it eliminates the need for cryogens and cooling. The new model offers 20% improved resolution, making it suitable for chemistry labs and educational purposes. Dr. Falko Busse emphasizes its role in democratizing FT-NMR applications, enabling greater accessibility for both research and teaching.
